Your browser doesn't support javascript.
Lessons from COVID-19 to increase opioid vaccine acceptance.
Damiescu, Roxana; Banerjee, Mita; Paul, Norbert W; Efferth, Thomas.
  • Damiescu R; Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, Mainz, Germany.
  • Banerjee M; Department of English and Linguistics, American Studies, Johannes Gutenberg University, Mainz, Germany.
  • Paul NW; Institute for History, Philosophy, and Ethics of Medicine, Johannes Gutenberg University Medical Center, Mainz, Germany.
  • Efferth T; Department of Pharmaceutical Biology, Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg University, Staudinger Weg 5, Mainz, Germany. Electronic address: efferth@uni-mainz.de.
Trends Pharmacol Sci ; 43(12): 998-1000, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-2256182
ABSTRACT
COVID-19 has put vaccine efficacy under a spotlight. However, the reluctance of people to be vaccinated has postponed the end of the COVID-19 pandemic. Currently, opioid vaccines are being developed, which could help prevent opioid addiction, overdoses, or relapse in combination with medication-assisted therapy. The fear is that the uptake of opioid vaccines could be met by the same reluctance as seen with COVID-19 vaccines.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Trends Pharmacol Sci Year: 2022 Document Type: Article Affiliation country: J.tips.2022.08.010

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Trends Pharmacol Sci Year: 2022 Document Type: Article Affiliation country: J.tips.2022.08.010